Deep Vein Thrombosis therapy - Biossil
Latest Information Update: 28 Nov 2025
At a glance
- Originator Biossil
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Deep vein thrombosis
Most Recent Events
- 15 Sep 2025 Phase-I clinical trials in Deep vein thrombosis (unspecified route) (Biossil pipeline, September 2025)